More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

"This is an area in which we haven't had something we felt hopeful about in a while," professor Joseph Schacht said.

An Amarillo doctor says that while lifestyle changes are necessary when trying to lose weight, it is not easy for many people ...

Achieving and maintaining a healthy weight is beneficial for a number of reasons. A healthy weight lowers a person's chance ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

A new report from Renub Research forecasts that the diabetes device market in China will grow from US$6.22 billion in 2023 to US$12.74 billion by 2032, representing a compound annual growth rate (CAGR ...

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...